Top

Published in:

01-12-2009

Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes

Authors: Valérie Chaudru, M. T. Lo, F. Lesueur, C. Marian, H. Mohamdi, K. Laud, M. Barrois, A. Chompret, M. F. Avril, F. Demenais, B. Bressac-de Paillerets

Published in: Familial Cancer | Issue 4/2009

Abstract

The effect of CDKN2A, the major high-risk melanoma susceptibility gene, has been shown to be modified by host-related phenotypes and variants of MC1R gene. The glutathione S-transferase (GSTs) genes, implicated in detoxification of metabolites after UV exposure, are candidates for modulating CDKN2A penetrance. Few case-control studies have investigated the effect of GSTs on melanoma risk, and have led to controversial results while these genes have not yet been studied in CDKN2A melanoma-prone families. We examined the effect of GSTP1, GSTM1 and GSTT1 genotypes on melanoma risk in 25 multi-generational melanoma-prone families with CDKN2A mutations, in presence of MC1R gene variants, sun exposure, and host-related phenotypes. These data included 195 genotyped subjects for all studied genes. We applied the GEE (Generalized Estimating Equations) approach to test for the effect of GSTs while adjusting for age, sex and CDKN2A mutation status and including successively MC1R, sun exposure and host factors in the model. No significant effect of null GSTM1 allele and GSTP1 variants (p.I105V, p.A114V) on melanoma risk was found. However, a significant protective effect of carrying ≥1 null GSTT1 allele was shown: OR_{adjusted for age,sex,CDKN2A} = 0.41 (0.18–0.94) and OR_{adjusted for age,sex,CDKN2A,MC1R} = 0.24 (0.15–0.58). Altogether, the factors modifying significantly the melanoma risk associated with CDKN2A mutations (stepwise procedure) were: MC1R and dysplastic nevi (increasing the risk) and GSTT1 (decreasing the risk). This study shows that even when a high-risk gene (CDKN2A) has been identified, multiple genetic modifiers influence melanoma risk.

Tucker MA, Goldstein AM (2003) Melanoma etiology: where are we? Oncogene 22:3042–3052. doi:10.1038/sj.onc.1206444 CrossRefPubMed

Goldstein AM, Chan M, Harland M et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:9818–9828. doi:10.1158/0008-5472.CAN-06-0494 CrossRefPubMed

Orlow I, Begg CB, Cotignola J et al (2007) CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 127:1234–1243. doi:10.1038/sj.jid.5700689 CrossRefPubMed

Bishop DT, Demenais F, Goldstein AM et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903PubMed

Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F (2004) Influence of genes, nevi, and sun-sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96:785–795PubMedCrossRef

Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA (2000) Genotype-phenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92:1006–1010. doi:10.1093/jnci/92.12.1006 CrossRefPubMed

Box NF, Duffy DL, Chen W et al (2001) MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765–773. doi:10.1086/323412 CrossRefPubMed

Chaudru V, Laud K, Avril MF et al (2005) Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14:2384–2390. doi:10.1158/1055-9965.EPI-04-0777 CrossRefPubMed

Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA (2005) Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 14:2208–2212PubMed

10.

van der Velden PA, Sandkuijl LA, Bergman W et al (2001) Melanocortin-1 receptor variant Arg151Cys modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69:774–779. doi:10.1086/323411 CrossRefPubMed

11.

Sturm RA, Teasdale RD, Box NF (2001) Human pigmentation genes: identification, structure and consequences of polymorphisms variations. Gene 277:49–62. doi:10.1016/S0378-1119(01)00694-1 CrossRefPubMed

12.

Kennedy C, ter Huurne J, Berkhout M et al (2001) Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 117:294–300. doi:10.1046/j.0022-202x.2001.01421.x CrossRefPubMed

13.

Matichard E, Verpillat P, Meziani R et al (2004) Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 41:e13. doi:10.1136/jmg.2003.011536 CrossRefPubMed

14.

Palmer JS, Duffy DL, Box NF et al (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66:176–186. doi:10.1086/302711 CrossRefPubMed

15.

Fargnoli MC, Argenziano G, Zalaudek I, Peris K (2006) High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 6:657–670. doi:10.1586/14737140.6.5.657 CrossRefPubMed

16.

Hayward N (2003) Genetics of melanoma predisposition. Oncogene 22:3053–3062. doi:10.1038/sj.onc.1206445 CrossRefPubMed

17.

Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51–88. doi:10.1146/annurev.pharmtox.45.120403.095857 CrossRefPubMed

18.

Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012. doi:10.1074/jbc.272.15.10004 CrossRefPubMed

19.

Casilli F, Di Rocco ZC, Gad S et al (2002) Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20:218–226. doi:10.1002/humu.10108 CrossRefPubMed

20.

Boos D (1992) On generalized score tests. Am Stat 46:327–333. doi:10.2307/2685328 CrossRef

21.

Goldstein AM, Chaudru V, Ghiorzo P et al (2007) Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from four countries. Int J Cancer 121:825–831. doi:10.1002/ijc.22712 CrossRefPubMed

22.

Dolzan V, Rudolf Z, Breskvar K (2006) Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat 15:69–78PubMed

23.

Mossner R, Anders N, Konig IR et al (2007) Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 298:371–379. doi:10.1007/s00403-006-0708-7 CrossRefPubMed

24.

Heagerty AH, Fitzgerald D, Smith A et al (1994) Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 343:266–268. doi:10.1016/S0140-6736(94)91115-0 CrossRefPubMed

25.

Kanetsky PA, Holmes R, Walker A et al (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10:509–513PubMed

26.

Shanley SM, Chenevix-Trench G, Palmer J, Hayward N (1995) Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis 16:2003–2004. doi:10.1093/carcin/16.8.2003 CrossRefPubMed

27.

Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M (1995) Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br J Cancer 72:324–326PubMed

28.

Parl FF (2005) Glutathione S-transferase genotypes and cancer risk. Cancer Lett 221:123–129. doi:10.1016/j.canlet.2004.06.016 CrossRefPubMed

29.

Roodi N, Dupont WD, Moore JH, Parl FF (2004) Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. Cancer Res 64:1233–1236. doi:10.1158/0008-5472.CAN-03-2861 CrossRefPubMed

30.

Wittgen HG, van Kempen LC (2007) Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 17:400–409. doi:10.1097/CMR.0b013e3282f1d312 CrossRefPubMed

31.

Reed DJ (1990) Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 30:603–631. doi:10.1146/annurev.pa.30.040190.003131 CrossRefPubMed

32.

Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Review. Cancer Epidemiol Biomarkers Prev 6:733–743PubMed

33.

Miyamura Y, Coelho SG, Wolber R et al (2007) Regulation of human skin pigmentation and responses to ultraviolet radiation. Review. Pigment Cell Res 20:2–13. doi:10.1111/j.1600-0749.2006.00358.x CrossRefPubMed

34.

Kadekaro AL, Kavanagh R, Kanto H et al (2005) Alpha-melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 65:4292–4299. doi:10.1158/0008-5472.CAN-04-4535 CrossRefPubMed

35.

Pavey S, Gabrielli B (2002) Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 62:875–880PubMed

36.

García-Borrón JC, Sánchez-Laorden BL, Jiménez-Cervantes C (2005) Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18:393–410PubMed

Title: Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes
Authors: Valérie Chaudru
M. T. Lo
F. Lesueur
C. Marian
H. Mohamdi
K. Laud
M. Barrois
A. Chompret
M. F. Avril
F. Demenais
B. Bressac-de Paillerets
Publication date: 01-12-2009
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9249-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

First case report of Muir–Torre syndrome associated with non-small cell lung cancer

Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population

Are prediction models for Lynch syndrome valid for probands with endometrial cancer?

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30

Cancer genetic predisposition: information needs of patients irrespective of risk level

A high frequent BRCA1 founder mutation identified in the Greenlandic population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer